Who Paid My Doc
Jason Cruff
Urogynecology and Reconstructive Pelvic Surgery Dearborn, MI Doctor of Osteopathy
NPI 1316205578 CMS profile 371678
22731 Newman St Ste 200, Dearborn, MI 48124
General payments
$11,871
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$10,650
Through program year 2025, Jason Cruff of Dearborn, MI is reported in the CMS Open Payments database as having received $11,871 across 52 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,650 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 83rd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,030 | 14 | |
| 2024 | General | $381 | 6 | |
| 2023 | General | $355 | 6 | |
| 2022 | General | $3,451 | 6 | |
| 2021 | General | $6,559 | 15 | |
| 2019 | General | $96 | 5 |
Beside peers
- Jason Cruff
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Jason Cruff were reported at $1,030. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Jason Cruff | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $96 | $358 | $132–$1,270 | $163 |
| 2020 | $0 | $198 | $86–$642 | $114 |
| 2021 | $6,559 | $361 | $118–$1,182 | $132 |
| 2022 | $3,451 | $410 | $128–$1,175 | $149 |
| 2023 | $355 | $434 | $152–$1,344 | $160 |
| 2024 | $381 | $494 | $193–$1,331 | $164 |
| 2025 | $1,030 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
1,025
Drug cost
$257,254
Branded share of claims
59.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 320 | $197,077 | |
| Gemtesa Vibegron | Brand | 60 | $34,530 | |
| Estradiol | Generic | 192 | $7,483 | |
| Darifenacin Er Darifenacin Hydrobromide | Brand | 35 | $4,761 | |
| Trospium Chloride Er Trospium Chloride | Brand | 33 | $4,631 | |
| Methenamine Hippurate | Generic | 68 | $3,357 | |
| Trospium Chloride | Generic | 56 | $3,132 | |
| Desmopressin Acetate | Generic | 18 | $509 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 69 | $434 | |
| Solifenacin Succinate | Generic | 13 | $409 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 53 billing codesPaid by Medicare
$67,204
Medicare patients
177
Services billed
673
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 62% | |
| Arthritis | 51% | |
| Osteoporosis | 33% | |
| Depression | 20% | |
| Diabetes | 18% | |
| Chronic kidney disease | 16% | |
| Cancer | 14% | |
| Heart failure | 11% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
52 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Michigan
Jannah Thompson
Urogynecology and Reconstructive Pelvic Surgery · Norton Shores, MI
Jason Bennett
Urogynecology and Reconstructive Pelvic Surgery · Grand Rapids, MI
John Delancey
Urogynecology and Reconstructive Pelvic Surgery · Ann Arbor, MI
Ali Luck
Urogynecology and Reconstructive Pelvic Surgery · West Bloomfield, MI
Salil Khandwala
Urogynecology and Reconstructive Pelvic Surgery · Dearborn, MI
Hope Bauer
Urogynecology and Reconstructive Pelvic Surgery · Grand Rapids, MI
Related records
Urogynecology and Reconstructive Pelvic Surgery in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.